Pulmonary drug delivery sales set to double:
This article was originally published in Clinica
Executive Summary
In four years' time, worldwide sales of pulmonary drug delivery products will have almost doubled to $15.2 billion, says a recent report from Front Line Strategic Management Consulting (Foster City, California). Average growth of 13% per year is expected, with new technologies, such as dry powder inhalers, and the phasing out of CFC systems and displacement of injectable therapies, contributing to the rise in sales. In 2001, sales of this category of product amountable to $8.4 billion, says the report. The US accounts for 44% of worldwide sales. The larger number of asthma sufferers and a favourable reimbursement policy from third-party payers makes the US a lucrative market.